Results 151 to 160 of about 21,385 (196)

Cardioprotective effect of CB1 receptor antagonist AM251 against β receptor-stimulated myocardial infarction via modulation of NF-kB signaling pathway in diabetic mice. [PDF]

Heliyon
Pawar HD, Patil Y, Patil A, Nakhate KT, Agrawal YO, Suchal K, Ojha S, Goyal SN.   +7 more
europepmc   +1 more source

Influence of structural characteristics on the binding of synthetic cannabinoids from the JWH family to the CB1 receptor: A computational study. [PDF]

J Mol Graph Model
Chaturvedi K, Anthony CS, Pandey P, Doerksen RJ, Godfrey M.   +4 more
europepmc   +1 more source

AM6527, a neutral CB1 receptor antagonist, suppresses opioid taking and seeking, as well as cocaine seeking in rodents without aversive effects. [PDF]

Neuropsychopharmacology
Soler-Cedeño O, Alton H, Bi GH, Linz E, Ji L, Makriyannis A, Xi ZX.   +6 more
europepmc   +1 more source

Internalization and Recycling of the CB1 Cannabinoid Receptor [PDF]

Journal of Neurochemistry, 1999
Abstract : Tolerance develops rapidly to cannabis, cannabinoids, and related drugs acting at the CB1 cannabinoid receptor. However, little is known about what happens to the receptor as tolerance is developing. In this study, we have found that CB1 receptors are rapidly internalized following agonist binding and receptor activation ...
K Mackie
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

The Cannabinoid CB1 Receptor in Schizophrenia

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021
Converging lines of evidence from epidemiological, preclinical, and experimental studies indicate that the endocannabinoid system may be involved in the pathophysiology of schizophrenia and suggest that the cannabinoid CB1 receptor may be a potential therapeutic target.
Faith Borgan, Michelle Kokkinou, Oliver Howes   +2 more
openaire   +3 more sources

Assay of CB1 Receptor Binding

2022
Type-1 cannabinoid receptor (CB1), one of the main targets of endocannabinoids, plays a key role in several pathophysiological conditions that affect both the central nervous system and peripheral tissues. Today, its biochemical identification and pharmacological characterization, as well as the screening of thousands of novel ligands that might be ...
Gasperi V, Savini I, Catani MV
openaire   +3 more sources

The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940)

Behavioural Pharmacology, 2005
It is well established that Cannabis sativa can increase appetite, particularly for sweet and palatable foods. In laboratory animals, cannabinoid CB1 receptor antagonism decreases motivation for palatable foods, and most recently, the CB1 receptor antagonist SR141716A, or rimonabant (Acomplia), was reported to produce weight loss in obese human ...
S J, Ward, L A, Dykstra
openaire   +2 more sources

CB1 Cannabinoid Receptor Ligands

Mini-Reviews in Medicinal Chemistry, 2005
The CB1 receptor is expressed in the central nervous system and numerous other tissues including heart, lung and uterus and has been recognized as an important therapeutic target for pain, appetite modulation, glaucoma, multiple sclerosis and other indications.
Ganesh A, Thakur, Spyros P, Nikas, Alexandros, Makriyannis   +2 more
openaire   +2 more sources

Assay of CB1 Receptor Binding

2016
Type-1 cannabinoid receptor (CB1), one of the main targets of endocannabinoids, plays a key role in several pathophysiological conditions that affect both central nervous system and peripheral tissues. Today, its biochemical identification and pharmacological characterization, as well as the screening of thousands of novel ligands that might be useful ...
Catani, VM, GASPERI, VALERIA
openaire   +4 more sources